Cara Therapeutics | CARA

Stock Price
12.14
Daily Change
-1.38%
Yearly
-19.07%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Chugai Pharma 3,550.00 22.00 0.62% -29.54%
Acadia Pharmaceuticals 19.40 0.61 3.25% -63.66%
AcelRx Pharmaceuticals 0.56 -0.01 -2.11% -61.32%
Aerie Pharmaceuticals 10.64 0.42 4.11% -16.68%
Arena Pharmaceuticals 50.07 0.52 1.05% -24.99%
Antares Pharma 3.26 0.11 3.49% -1.21%
BioDelivery Sciences International 2.60 0.02 0.78% -37.95%
Cara Therapeutics 12.14 -0.17 -1.38% -19.07%
Depomed 1.36 0.01 0.74% 222.96%
Endo International Ordinary Shares 5.02 0.03 0.60% -4.38%
Halozyme Therapeutics 32.83 0.43 1.33% -18.82%
Horizon Pharma 98.56 -1.28 -1.28% 41.06%
Jazz Pharmaceuticals 121.51 1.25 1.04% -18.14%
J&J 162.94 3.56 2.23% 9.38%
Neurocrine Biosciences 80.69 1.01 1.27% -11.40%
Pacira 54.10 1.57 2.99% -9.85%
Pfizer 51.48 -2.79 -5.14% 24.80%
Cassava Sciences Inc. 43.96 -1.89 -4.12% 481.48%
RedHill Biopharma 2.65 0.10 3.92% -69.40%
Revance Therapeutics 14.58 -0.02 -0.14% -39.22%
Supernus Pharmaceuticals 30.07 -0.32 -1.05% 39.86%
Teva Pharmaceutical Industries 8.24 0.19 2.36% -18.09%
Vanda Pharmaceuticals 16.02 -0.20 -1.23% 20.91%

Indexes Price Day Year
NASDAQ 15225 139.68 0.93% 21.61%
US2000 2203 44.17 2.05% 16.51%

Cara Therapeutics
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.